Monaco Asset Management SAM Has $1.01 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Monaco Asset Management SAM lowered its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 50.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,000 shares of the company’s stock after selling 50,000 shares during the quarter. Monaco Asset Management SAM’s holdings in Teva Pharmaceutical Industries were worth $1,010,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. Howard Bailey Securities LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 3.5% during the 3rd quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock worth $292,000 after buying an additional 494 shares during the period. ASR Vermogensbeheer N.V. raised its position in Teva Pharmaceutical Industries by 1.6% during the third quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock valued at $645,000 after purchasing an additional 515 shares in the last quarter. Retirement Planning Co of New England Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 1.8% during the 3rd quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock worth $671,000 after buying an additional 588 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in Teva Pharmaceutical Industries by 0.5% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,209 shares of the company’s stock valued at $1,981,000 after acquiring an additional 615 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in Teva Pharmaceutical Industries by 6.1% during the third quarter. Smartleaf Asset Management LLC now owns 10,794 shares of the company’s stock worth $207,000 after acquiring an additional 624 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TEVA shares. The Goldman Sachs Group raised their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Truist Financial raised their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Finally, Jefferies Financial Group raised their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average target price of $37.56.

Insider Activity

In other news, insider Mark Sabag sold 216,892 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the sale, the insider directly owned 52,828 shares in the company, valued at $1,517,748.44. This represents a 80.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president directly owned 48,384 shares of the company’s stock, valued at approximately $1,387,653.12. This trade represents a 70.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 422,060 shares of company stock valued at $12,254,965. Company insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.3%

Shares of NYSE:TEVA opened at $34.24 on Friday. The firm has a market cap of $39.37 billion, a P/E ratio of 28.53, a P/E/G ratio of 11.49 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $37.35. The business has a fifty day simple moving average of $32.57 and a 200 day simple moving average of $25.07. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm’s revenue was up 11.4% compared to the same quarter last year. During the same period last year, the company earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.